×
About 36,589 results

ALLMedicine™ Hepatitis B Virus Center

Research & Reviews  17,881 results

Current and past infections of hepatitis B virus do not increase mortality in patients ...
https://doi.org/10.1002/hep.31890
Hepatology (Baltimore, Md.); Yip TC, Wong VW et. al.

May 7th, 2021 - We compared risk of acute liver injury and mortality in COVID-19 patients with current, past, and no hepatitis B virus (HBV) infection. This was a territory-wide retrospective cohort study in Hong Kong. COVID-19 patients between 23 January 2020 an...

The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog ...
https://doi.org/10.1016/j.jhep.2021.04.040
Journal of Hepatology; Berg T, Lampertico P

May 6th, 2021 - Although discontinuation of nucleos(t)ide analogue (NA) treatment before HBsAg loss is part of all current hepatitis B virus (HBV) treatment guidelines for HBeAg-positive patients who achieved HBeAg seroconversion, a treatment endpoint known to be...

Hepatitis B virus prevalence in first-time blood donors in Flanders, Belgium: Impact of...
https://doi.org/10.1111/trf.16431
Transfusion De Brier N, Koc ÖM et. al.

May 6th, 2021 - Transfusion-transmissible infections such as hepatitis B virus (HBV) remain a major concern for the safety of blood transfusion. This cross-sectional study aimed to assess the trend of HBV prevalence and associated risk factors among a first-time ...

The Landscape of Cell-free HBV Integrations and Mutations in Cirrhosis and Hepatocellul...
https://doi.org/10.1158/1078-0432.CCR-21-0002
Clinical Cancer Research : an Official Journal of the Ame... Zheng B, Liu X et. al.

May 5th, 2021 - Intratumoral hepatitis B virus (HBV) integrations and mutations are related to hepatocellular carcinoma (HCC) progression. Circulating cell-free DNA (cfDNA) has shown itself as a powerful non-invasive biomarker for cancer. However, the HBV integra...

see more →

Guidelines  51 results

Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Serv...
https://doi.org/10.1001/jama.2020.22980
JAMA , Krist AH et. al.

Dec 15th, 2020 - An estimated 862 000 persons in the US are living with chronic infection with hepatitis B virus (HBV). Persons born in regions with a prevalence of HBV infection of 2% or greater, such as countries in Africa and Asia, the Pacific Islands, and part...

Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: A...
https://doi.org/10.1200/JCO.20.01757
Journal of Clinical Oncology : Official Journal of the Am... Hwang JP, Feld JJ et. al.

Jul 27th, 2020 - This Provisional Clinical Opinion update presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management. All patients anticipating systemic anticancer therapy should be tested for HBV by 3 tests-hepatitis B surface an...

Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update
https://ascopubs.org/doi/full/10.1200/JCO.20.01757
Journal of Clinical Oncology; Hwang JP

Jul 26th, 2020 - This Provisional Clinical Opinion update presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management.

Management of hepatitis B virus infection, updated Swedish guidelines.
https://doi.org/10.1080/23744235.2019.1675903
Infectious Diseases (London, England); Westin J, Aleman S et. al.

Oct 15th, 2019 - Despite access to effective antiviral drugs and vaccines, hepatitis B virus (HBV) infection remains a major health issue worldwide. HBV is highly infectious and may cause chronic infection, progressive liver damage, hepatocellular cancer (HCC) and...

Screening for Hepatitis B Virus Infection in Pregnant Women US Preventive Services Task Force Reaffirmation Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2738558
JAMA

Jul 22nd, 2019 - Screening for hepatitis B virus (HBV) infection during pregnancy identifies women whose infants are at risk of perinatal transmission. Data from a nationally representative sample showed a prevalence of maternal HBV infection of 85.8 cases per 100...

see more →

Drugs  21 results see all →

Clinicaltrials.gov  18,237 results

Current and past infections of hepatitis B virus do not increase mortality in patients ...
https://doi.org/10.1002/hep.31890
Hepatology (Baltimore, Md.); Yip TC, Wong VW et. al.

May 7th, 2021 - We compared risk of acute liver injury and mortality in COVID-19 patients with current, past, and no hepatitis B virus (HBV) infection. This was a territory-wide retrospective cohort study in Hong Kong. COVID-19 patients between 23 January 2020 an...

The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog ...
https://doi.org/10.1016/j.jhep.2021.04.040
Journal of Hepatology; Berg T, Lampertico P

May 6th, 2021 - Although discontinuation of nucleos(t)ide analogue (NA) treatment before HBsAg loss is part of all current hepatitis B virus (HBV) treatment guidelines for HBeAg-positive patients who achieved HBeAg seroconversion, a treatment endpoint known to be...

Hepatitis B virus prevalence in first-time blood donors in Flanders, Belgium: Impact of...
https://doi.org/10.1111/trf.16431
Transfusion De Brier N, Koc ÖM et. al.

May 6th, 2021 - Transfusion-transmissible infections such as hepatitis B virus (HBV) remain a major concern for the safety of blood transfusion. This cross-sectional study aimed to assess the trend of HBV prevalence and associated risk factors among a first-time ...

The Landscape of Cell-free HBV Integrations and Mutations in Cirrhosis and Hepatocellul...
https://doi.org/10.1158/1078-0432.CCR-21-0002
Clinical Cancer Research : an Official Journal of the Ame... Zheng B, Liu X et. al.

May 5th, 2021 - Intratumoral hepatitis B virus (HBV) integrations and mutations are related to hepatocellular carcinoma (HCC) progression. Circulating cell-free DNA (cfDNA) has shown itself as a powerful non-invasive biomarker for cancer. However, the HBV integra...

see more →

News  397 results

Treatment Paradigm for Chronic HBV in Flux
https://www.medscape.com/viewarticle/948611

Apr 1st, 2021 - These days deciding when to stop targeted treatment for chronic hepatitis B is a bigger challenge than knowing when to start, Norah A. Terrault, MD, MPH, observed at the Gastroenterology Updates, IBD, Liver Disease Conference. That's because the t...

USPSTF Reaffirms Advice on HBV Screening in High-Risk Individuals
https://www.medscape.com/viewarticle/942681

Dec 15th, 2020 - NEW YORK (Reuters Health) - The U.S. Preventive Services Task Force (USPSTF) continues to recommend screening for hepatitis B virus (HBV) in nonpregnant adolescents and adults at increased risk for HBV infection, concluding with "moderate certaint...

Serum Hep B Virus RNA Levels Useful When Deciding When to Stop Treatment
https://www.staging.medscape.com/viewarticle/936294

Aug 25th, 2020 - NEW YORK (Reuters Health) - Patients with chronic hepatitis B who have undetectable serum hepatitis B virus (HBV) RNA can safely undergo cessation of entecavir antiviral treatment, according to a new study. "Serum HBV RNA reflects an important int...

Serum Hep B Virus RNA Levels Useful When Deciding When to Stop Treatment
https://www.medscape.com/viewarticle/936294

Aug 25th, 2020 - NEW YORK (Reuters Health) - Patients with chronic hepatitis B who have undetectable serum hepatitis B virus (HBV) RNA can safely undergo cessation of entecavir antiviral treatment, according to a new study. "Serum HBV RNA reflects an important int...

Renal Dysfunction Improves Following Switch From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
https://www.medscape.com/viewarticle/935890

Aug 18th, 2020 - NEW YORK (Reuters Health) - In HIV/hepatitis B virus (HBV)-coinfected individuals with renal dysfunction, renal function improves after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF), according to results from a ...

see more →

Patient Education  2 results see all →